Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of Mirabegron on Psychological Distress and Bladder Blood Flow in Female OAB
NCT03695822Phase 4Withdrawn
- Sponsor
- Far Eastern Memorial Hospital
- Start
- Dec 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mirabegron in overactive bladder syndrome (OAB), sponsored by Far Eastern Memorial Hospital. Primary endpoint: Brief Symptom Rating Scale at 12 weeks. Planned start Dec 2018; status: withdrawn.
02
Drugs
mirabegron
03
Conditions
overactive bladder syndrome (OAB)
Beyond the preview
Go deeper on NCT03695822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03695822.